Pharmaceuticals News and Research

RSS

Genoa Pharmaceuticals, McMaster University report additional benefits of GP-101 for IPF patients

Genoa Pharmaceuticals, the leader in inhaled medicines for pulmonary fibrosis, and collaborators Drs. Martin Kolb and Kjetil Ask at McMaster University announced today additional measured advantages of inhaled GP-101 (aerosol pirfenidone) in the treatment of idiopathic pulmonary fibrosis (IPF).

21 Apr 2014

New insights into possible common links between neurodegenerative diseases

The pattern of brain alterations may be similar in several different neurodegenerative diseases, which opens the door to alternative therapeutic strategies to tackle these diseases

21 Apr 2014

Cyclenium Pharma signs drug discovery and development agreement with Southern Research Institute

Cyclenium Pharma Inc., an emerging pharmaceutical company specializing in the research and development of novel drug candidates based on proprietary macrocyclic chemistry, today announced the signing of a discovery and co-development agreement with Southern Research Institute, a not-for-profit 501(c)(3) scientific research organization founded in 1941.

18 Apr 2014

Drug used to treat TB may also act against various infections, says study

A drug under clinical trials to treat tuberculosis could be the basis for a class of broad-spectrum drugs that act against various bacteria, fungal infections and parasites, yet evade resistance, according to a study by University of Illinois chemists and collaborators.

18 Apr 2014

ARCA biopharma announces genetic screening of first patient in GENETIC-AF Phase 2B/3 clinical trial

ARCA biopharma, Inc., a biopharmaceutical company developing genetically targeted therapies for cardiovascular diseases, today announced that the first patient has been genetically screened in GENETIC-AF, its Phase 2B/3 adaptive design clinical trial.

From Medtronic 18 Apr 2014

13th annual Bio-IT World Conference & Expo to launch new disciplinary track on data security

The 13th annual Bio-IT World Conference & Expo, to be held April 29-May 1 at the Seaport World Trade Center in Boston, today announced that it will debut a new disciplinary track focused on data security.

18 Apr 2014

Agios begins AG-348 Phase 1 study to treat PK deficiency

Agios Pharmaceuticals, Inc., a leader in the fields of cancer metabolism and inborn errors of metabolism (IEM), today announced dose administration of AG-348 in a Phase 1 study in healthy volunteers.

18 Apr 2014

Actavis to purchase four currently marketed products from Akorn

Actavis plc, a leading global specialty pharmaceutical company, today announced that it has entered into agreements with Akorn, Inc. and Hi-Tech Pharmacal Co. Inc. to purchase four currently marketed products and one product under development

18 Apr 2014

Neutra to unveil new vapor pen at Cannabis Cup trade show

The executive leadership from Neutra Corp. will travel to Denver this week to seek out distribution and build brand awareness for the company's new vapor pen at one of the world's largest cannabis conventions: the Cannabis Cup.

17 Apr 2014

Cancer Research partners with AstraZeneca and Pfizer to create clinical trial for advanced lung cancer

CANCER RESEARCH UK is partnering with pharmaceutical companies AstraZeneca and Pfizer to create a pioneering clinical trial for patients with advanced lung cancer - marking a new era of research into personalised medicines to treat cancer.

17 Apr 2014

Neurovive presents new breakthrough on energy regulation at cellular level

NeuroVive, a leading mitochondrial medicine company, is presenting a breakthrough in the company's work on energy regulation at the cellular level.

17 Apr 2014

Researchers create clinical trial for patients with advanced lung cancer

Cancer Research UK is partnering with pharmaceutical companies AstraZeneca and Pfizer to create a pioneering clinical trial for patients with advanced lung cancer - marking a new era of research into personalised medicines to treat cancer.

17 Apr 2014

Top performing oncology drugs at risk of losing patent rights by 2022

After a period of relative stability, a glut of patent expiries is just five years away for the oncology market, according to pharmaceutical analyst Datamonitor Healthcare.

17 Apr 2014

Free medication samples in dermatology offices appear to change prescribing practices for acne

The availability of free medication samples in dermatology offices appears to change prescribing practices for acne, a common condition for which free samples are often available.

17 Apr 2014

Iconic Therapeutics completes $20 million Series B-1 equity financing

Iconic Therapeutics, Inc., a biotechnology company focused on developing therapeutics for serious eye disorders, announced today that it has successfully completed a $20 million Series B-1 equity financing from new investors MPM Capital, Lundbeckfond Ventures, and H.I.G. BioVentures.

16 Apr 2014

Epirus Biopharmaceuticals to merge with Zalicus

Zalicus Inc., and Epirus Biopharmaceuticals, Inc., a Boston-based biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies, announced today that they have entered into a definitive agreement under which Epirus will merge with a wholly-owned subsidiary of Zalicus in an all-stock transaction.

16 Apr 2014

UTMB experts honored with Lifetime Achievement Award for contributions to study of deadly diseases

The global experts who study the deadliest infectious diseases recognized the contributions of Frederick A. Murphy and Thomas G. Ksiazek, professors at the University of Texas Medical Branch, with a Lifetime Achievement Award at the 6th annual International Symposium on Filoviruses. The filoviruses include Ebola and Marburg viruses that cause death in 50 to 90 percent of people infected. The current outbreak of Ebola virus raging in West Africa has caused more than 100 deaths so far.

16 Apr 2014

Wilson Therapeutics closes $40 million Series B financing

Wilson Therapeutics, a biopharmaceutical company, today announced that it has closed a $40 million Series B financing co-led by new investors, Abingworth LLP and MVM Life Science Partners LLP. The company's founding investor, HealthCap, also participated in the round.

16 Apr 2014

Genetically modified neural stem cells offer potential treatment for Alzheimer's disease

UC Irvine neurobiologists have found that genetically modified neural stem cells show positive results when transplanted into the brains of mice with the symptoms and pathology of Alzheimer's disease. The pre-clinical trial is published in the journal Stem Cells Research and Therapy, and the approach has been shown to work in two different mouse models.

16 Apr 2014

Akebia completes enrollment in ongoing 200-patient Phase 2b study of AKB-6548

Akebia Therapeutics, Inc., a biopharmaceutical company focused on the development of novel proprietary therapeutics based on hypoxia-inducible factor (HIF) biology and the commercialization of these products for patients with kidney disease, today announced it has completed enrollment in its ongoing 200-patient Phase 2b study of AKB-6548 for the treatment of anemia associated with chronic kidney disease (CKD) in patients who are not dependent on dialysis.

16 Apr 2014

Pharmaceuticals News and Research

Genoa Pharmaceuticals, McMaster University report additional benefits of GP-101 for IPF patients

New insights into possible common links between neurodegenerative diseases

Cyclenium Pharma signs drug discovery and development agreement with Southern Research Institute

Drug used to treat TB may also act against various infections, says study

ARCA biopharma announces genetic screening of first patient in GENETIC-AF Phase 2B/3 clinical trial

13th annual Bio-IT World Conference & Expo to launch new disciplinary track on data security

Agios begins AG-348 Phase 1 study to treat PK deficiency

Actavis to purchase four currently marketed products from Akorn

Neutra to unveil new vapor pen at Cannabis Cup trade show

Cancer Research partners with AstraZeneca and Pfizer to create clinical trial for advanced lung cancer

Neurovive presents new breakthrough on energy regulation at cellular level

Researchers create clinical trial for patients with advanced lung cancer

Top performing oncology drugs at risk of losing patent rights by 2022

Free medication samples in dermatology offices appear to change prescribing practices for acne

Iconic Therapeutics completes $20 million Series B-1 equity financing

Epirus Biopharmaceuticals to merge with Zalicus

UTMB experts honored with Lifetime Achievement Award for contributions to study of deadly diseases

Wilson Therapeutics closes $40 million Series B financing

Genetically modified neural stem cells offer potential treatment for Alzheimer's disease

Akebia completes enrollment in ongoing 200-patient Phase 2b study of AKB-6548

A guide to density measurement excellence eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Managing vibration in IVF laboratories

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence